deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03468218

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN

Sponsor: Emory University

Conditions Metastatic Head and Neck Carcinoma Paranasal Sinus Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 Unresectable Head and Neck Squamous Cell Carcinoma
Interventions Cabozantinib Pembrolizumab
Updated 16 times since 2018 Last updated: Jan 6, 2026 Started: Sep 18, 2018 Primary completion: May 2, 2022 Completion: Oct 29, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03468218, this PHASE2 trial focuses on Metastatic Head and Neck Carcinoma and Paranasal Sinus Squamous Cell Carcinoma and remains ongoing. Sponsored by Emory University, it has been updated 16 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2018 – ~Oct 2018 · 6 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Dec 2020 · 12 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Mar 2022 · 11 months · monthly snapshot~Mar 2022 – ~Mar 2023 · 12 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Mar 2025 · 59 days · monthly snapshot~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Mar 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  4. Apr 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Dec 2019 — Dec 2020 [monthly]

    Recruiting PHASE2

  8. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  9. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  10. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Apr 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Emory University
  • Exelixis
  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations